Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On May 21, 2024, Enveric Biosciences, Inc. (the "Company") received a letter from the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market ("Nasdaq") notifying the Company that it regained compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(1) (the "Minimum Stockholders' Equity Clearance Letter"). As reported in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, the Company's total stockholders' equity as of March 31, 2024 was $6,481,856.
Receipt of the Minimum Stockholders' Equity Clearance Letter has no effect on the Company's minimum bid price deficiency pursuant to Nasdaq Listing Rule 5550(a)(2), as reported by the Company on Current Report on Form 8-K filed with the Securities and Exchange Commission on May 17, 2024. The Company intends to continue to actively monitor the bid price for its common stock and consider available options to resolve the deficiency and regain compliance.
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as "plans,"" expects" or "does not expect," "proposed," "budgets," "scheduled," "estimates," "forecasts," "intends," "anticipates" or "does not anticipate," or "believes," or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. Forward-looking statements may include historical statements and statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of various factors. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable based on information currently available, the Company cannot assure you that the expectations will prove to have been correct. Accordingly, you should not place undue reliance on these forward-looking statements. In any event, these statements speak only as of the date of this Current Report on Form 8-K. The parties undertake no obligation to revise or update any of the forward-looking statements to reflect events or circumstances after the date of this Current Report on Form 8-K or to reflect new information or the occurrence of unanticipated events.
Attachments
Disclaimer
Enveric Biosciences Inc. published this content on 23 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 May 2024 12:02:25 UTC.
